Damnthe, are you a new investor in CTIX? If so, did buy in because CTIX acquired Polymeds assets? Wondering if CTIX is getting some new investors that were once Polymed holders?
How CTIX got Brilacidin at the price they did is still a wonderment to me. Did Polymed investors question the Brilacidin phase2a success in light of a potential cover up with 60056? Why didn't Cubist take it? They were in the buying mood. I know the trials locations for p2a where from Canada, Russia and Ukraine is this a troublesome area for clinical trials?
I should write to Cubist IR and question them on why they didn't pursue Brilacidin they would probably think I am investor in their company.
Not bashing here so please no hate mail, just curious.
Tails,
There is some risk with Brilacidin. I was a heavy investor in Polymedix and in it at the time management blindsided us with PMX-60056 blood pressure problems. Since the two products are fairly closely related, concerns are valid.
That said, there didn't appear to be any similar problems with Brilacidin P2a, but who knows? In many of our (PYMX investors) minds, management withheld material information regarding PMX-60056 long after they knew of the BP problems. In fact, the announcement of trial discontinuation was the beginning of the end for the company, as well as the trigger for numerous lawsuits.
Many of us wondered how a product (Brilacidin) that had so much potential and displayed supposedly superior efficacy to its competition could not be picked up by a major pharmaceutical. I think a number of us were quite suprised to see a small biotech like Cellceutix buy Polymedix' assets for such a low price rather than a big pharmaceutical. It makes me wonder...
News 
Market Data 
Discover 
